BioSpace News Archive

Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (“Justera” or the “Company”) is pleased to announce that the Company’s wholly-owned subsidiary, Juillet Wellness Centre (“Juillet Wellness”), has seen a significant revenue boost following the introduction of its premium laser treatment services, powered by CUTERA XEO (“XEO”).

In observance of World AMR Awareness Week (WAAW), Magnolia Medical Technologies, Inc., the inventors of the Steripath® Initial Specimen Diversion Device® (ISDD®) and the ISDD market to prevent false-positive sepsis tests, is driving efforts to highlight the role of diagnostic stewardship in combating the risk of AMR.

Nicklaus Children’s Hospital is to become only the third site in North America involved in a Phase I clinical trial studying the role of a new technology called low-frequency focused ultrasound in the care of children with a lethal type of brain tumor that forms within the brainstem.

Immuneering Corporation announced that management will present at the 35th Annual Piper Sandler Healthcare Conference to discuss the company’s pipeline, platform, and business strategy.

Tempest Therapeutics, Inc. announced that management will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference on Tuesday, November 28, 2023 at 3:00 p.m. ET.

TRACON Pharmaceuticals, Inc. announced it has licensed its proprietary PDP of CRO-independent clinical research to a clinical stage biotech company for a $3.0 million upfront payment.

Yamo Pharmaceuticals LLC, a clinical stage pharmaceutical company, announced that it has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorder.

Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders announced that representatives of Anavex met with team members of the European Medicines Agency.

Ascendis Pharma A/S announced that the European Commission has granted marketing authorization for YORVIPATH® as replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism.

Avenge Bio, Inc. announced Michael Heffernan, Founder and Chief Executive Officer, will present at the Piper Sandler 35th Annual Healthcare Conference in New York.